Biotech

0 1186
Synergy Pharmaceuticals Inc SGYP Stock News

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals is having a rough time in the market as of late. In fact, the stock’s price has been falling on a nearly daily basis. However, one of Warren Buffet’s biggest lessons is to buy when fear is high, and there’s a strong argument at the moment that while SGYP is weak, it represents some serious horsepower in terms of opportunity.





The SGYP Opportunity Lies In Trulance

When Synergy Pharmaceuticals received FDA approval for Trulance, the stock went wild. However, since then, excitement has died down a bit, and so too has the stock price. This is normal when it comes to first time FDA approvals in these small biotech companies, and historically, it actually represents a strong opportunity.

You see, at the moment, investors are in the wait-and-see mode that they were in shortly after Gilead Sciences got their first FDA approval. Of course, we all know where the company is today! The truth is that if SGYP does what it needs to do with Trulance, it will put itself on a beeline toward major success, and that will send the price skyrocketing.




Analysts Are Betting On Opportunity

Just yesterday, an analyst weighed in on SGYP, betting that the current weakness represents a strong opportunity. That analyst was Timothy Chiang of BTIG. In his note, he reiterated a Buy rating with an $11 price target, pointing to Trulance as the primary reason for his bullish opinion. Here’s what he had to say:

With the US launch of Trulance (3mg plecanatide, for the treatment of chronic constipation) now officially underway, investor focus now turns to the ramp for trulance in the US market. We continue to believe management is up to the task of successfully launching Trulance via its hybrid sales model (utilizing an experienced contract sales force of ~150 – 200 reps), which is expected to target ~27,000 high-prescribing physicians. While we believe formulary access for Trulance could take up to 6 months, we think most insurance plans will put Trulance on a Tier 3 co-pay, with the Co. offering its “savings to go” program as an offset. Our channel checks with several local pharmacies in NYC this morning suggest that this program will enable patients to get access to Trulance at a much lower cost (no more than $25 per Rx). Management also recently highlighted at an investor conference earlier today that a nationwide sampling program is underway. In sum, we expect the launch of Trulance to lead to more patients switching from OTC laxatives to Rx treatments, with Trulance leading to an expansion of the overall Rx market.”

The Bottom Line

The bottom line here is that chances are that SGYP has something big with Trulance. Considering their planned marketing of the treatment, chances are that it will quickly fly off of the shelves. With the stock currently trading far lower than it should (in my opinion), now may be the perfect time to consider adding the stock to your portfolio.

What Do You Think?

Where do you think SGYP is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required











[Image Courtesy of Flickr]

0 412
Idera Pharmaceuticals Inc IDRA Stock News

Idera Pharmaceuticals Inc (NASDAQ: IDRA)

Idera Pharmaceuticals is having an incredible day in the market today. The movement in the stock is driven by news that JPM securities has initiated coverage on the stock, and they have a positive view overall. As a result of the news, the stock spiked, causing our partners at Trade Ideas to send the alert. At the moment (10:01), IDRA is trading at $2.28 per share after a gain of $0.19 per share or 8.85% thus far today.





JPM Securities Initiates IDRA Coverage

As mentioned above, the gains that we saw in after-hours and the pre-market are the result of JPM securities making the decision to initiate coverage on the biopharmaceutical company. In a note, JPM Securities Analyst, Michael King said that IDRA is “Capable of generating a host of promising drug candidates,” He went on to explain that he is impressed with the company’s work thus far in the space of immunology, stating that they have shown “impressive clinical activity in combination with checkpoint inhibition in the setting of anti-PD-1 refractory metastatic melanomoa.”




As a result of his strong opinion on the stock, King initiated coverage on Idera Pharmaceuticals with a rating of market outperform as well as a price target of $8.

What We’ll Be Watching For

Moving forward, the CNA Fiannce team will be watching IDRA incredibly closely. In particular, we’ll be watching the company’s continued work in the field of oncology and we are excited to see the progress the company continues to make. Nonetheless, we’ll be watching closely and bringing you the news as it breaks!

What Do You Think?

Where do you think IDRA is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 836
Pernix Therapeutics Inc PTX Stock News

Pernix Therapeutics Holdings Inc (NASDAQ: PTX)

Let’s keep it real. I am long Pernix stock and, while I may have gotten to the point of where I play hide and seek with the daily share price fluctuations, I am far from throwing in the towel on this company. I’m not stubborn to the point of becoming poor, nor do I enjoy frequent episodes of pain. Rather, I tend to have the ability to cut through the minutia and get to the nitty gritty of the issue at hand, and, as for the issue at PTX, I still see significant upside value in PTX.





Don’t call me crazy, and please don’t call me “surely,” but when I take a good, long look at PTX, I see far more potential and intrinsic value in the shares than is currently being represented by the stock price.

From There To Here

For many shareholders, the lingering pain of the 1:10 reverse split still causes some sleepless nights, but, from a strategic standpoint, the r/s provided some much-needed ammunition in times of need, leaving a considerably low share count that can raise significant capital at current or even discounted prices. Far removed from the threat of being delisted, PTX now trades at roughly $3.90 a share, battling back feverishly from the previous month trading lows of $2.74. Additionally, with approximately 9.5 million shares outstanding, PTX has a plethora of options available to them to keep the momentum going, inclusive of favorable court decisions, a stout IP portfolio and a pipeline of franchise quality drugs that can return considerable value shortly. For the number hawks, PTX is scheduled to announce Q4 earnings next Tuesday, so expect that a lot of trading eyes will be focused toward PTX on that day, with perhaps more funneled interest in management’s comments than they have in results from months past.

Yes, I want to hear about growth and continued traction in the currently marketed drugs, but, indeed, investors are looking to understand considerably more about the hardball being played with creditors. Investors want guidance as to the impact of the recent court decisions and the strategic options that are now in play based on the company prevailing in the Zohydro ER ANDA litigation.

For those that were not paying attention, in late February, PTX announced that they had received a favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER. In a release by PTX, the company stated, “Judge Gregory M. Sleet of the United States District Court for the District of Delaware concluded that Actavis’ proposed generic versions of Zohydro ER infringe U.S. Patent Nos. 9,132,096 (which expires on September 12, 2034) and 6,902,742 (which expires on November 1, 2019) following a trial that took place in October 2016. The Judge has entered an order enjoining Actavis from engaging in the commercial manufacture, use, offer to sell, or sale in the United States, or importation into the United States of Actavis’ Abbreviated New Drug Application (ANDA) product prior to expiration of the two patents. Actavis did not assert invalidity or unenforceability of the patents at trial.”

Not only was the decision a potential windfall for PTX, but it also served to validate the strength and longevity of the Zohydro ER patent portfolio. It further allows PTX to advance the Zohydro franchise well into the future, without the continued overhang of litigation and uncertain legal opinions. For investors, the decision acted as a pressure valve release, and the stock has been on an ascent ever since. The patents are strong, and the litigation appears to be ending. Both patents are listed in the FDA’s “Orange Book” for Zohydro ER and are licensed to Pernix by Recro Gainesville LLC. Recro and another generic pharmaceutical manufacturer, Alvogen Malta Operations Ltd., filed a stipulation of dismissal last year ending a patent infringement lawsuit Recro filed against Alvogen concerning its proposed generic version of Zohydro ER. Thus, for the time being, we, the shareholders and PTX, are free at last.

Some Good, Some…Not So Good

Those that have kids know that way too often after a child has one of these strong belly laugh attacks, it is quite frequently followed with a voracious cry. I’m not sure why we were created in that fashion, but perhaps it’s because our maker wanted to make sure we knew that there was balance in life.

Such was the case at PTX when investors were told that the company had lost its arbitration case. On February 3, 2016, PTX announced that “On January 31, 2017, the arbitration tribunal issued opinions in favor of GSK, awarding it damages and fees in the amount of approximately $35 million, plus interest (estimated to be approximately $2 to $5 million). The tribunal also denied Pernix’s claim that GSK breached its obligations under the supply agreement. Pernix has already paid to GSK, or into an escrow account, an aggregate of $16.5 million, which will offset the total award. Pernix is reviewing the opinions, including the amount of interest, and intends to work with GSK to conclude the matter.

As of February 1, 2017, Pernix’s unaudited cash balance was approximately $26 million, after making the scheduled payment of interest and principal in respect of its Treximet secured notes on such date.”

On that day, the sun was definitely not shining on my face. But, balance reared its beautiful face and by the time February ended, the sun was not only shining back on my face but the company’s primary cash cow, Zyhodro ER was fully back in play.

Such is life; you win some, you lose some. But, by the time February came to a close, PTX, at least in my opinion, is in a better place than at the start of the year. Removed are the storm clouds of legal uncertainty. And, with a clear path for Zyhodro ER, PTX can cut a deal on the remaining $18.5 million owed and concentrate on rebuilding the PTX brand and continue to deliver product traction and better financial results.

Where To Now

PTX is not alone in the quest to be reincarnated as a beautiful stock. There are more than a handful of other drug stocks that have a similar story, Valeant Pharmaceuticals (VRX), Infinity Pharmaceuticals (INFI), and Portola Pharmaceuticals (PTLA), just to name a few. And, like PTX, both Infinity and Portola have rallied back hard since the beginning of 2017. As for Valeant, the market, and Congress, still needs a poster child, and they seem to have monopolized that position, for now, sliding over 50% lower since the beginning of the year. Seeing that there can still be some good in the bad, though, gives me hope. And, if there were a way to siphon and share some of that good karma away from Infinity and Portola, I would.

Maybe I am just an eternal optimist, but I no longer obsess about past PTX transgression and focus even less on waiting for new skeletons to materialize from PTX attic. Heck, PTX is its own concern, not a subsidiary of the Bates Motel. Investors, myself included, may finally be able to take a breath of fresh air and give PTX management the time necessary to fully right this ship and create shareholder value.

If they want to spook the creditors, I’m all for it, sell a couple of million shares when needed, shore up the balance sheet and let the predators understand that the value in PTX is there for the taking, but at prices far more than the current value. The Gordon Gecko, Blue Star Airline approach to conquer and divide is so totally 1980’s. Scrapping the pieces of a viable company is old school mentality. Investors today understand that while in extreme cases of distress, perhaps breaking up small pieces and salvaging them at pennies on the dollar makes sense. But, there can’t be an argument made that doing the same at PTX makes sense.




PTX has a franchise drug in place, a well fortified IP portfolio, and a decent cash balance that can carry the company forward during the next round of investor “fake news” and general market turmoil. PTX management are not new kids on the block, and they will ultimately deliver back shareholder value, and rightfully so since that’s what they get paid to do. While high double-digit share prices may very well be a thing of the past, once management clearly proves that the company is indeed tracking in the right direction and churning all the pistons, then it is not unimaginable to believe that share prices won’t be printed at considerably higher prices than where they are today.

I can take criticism, and I can take a loss. But, just because I can handle it does not mean that I deserve it. I’m not the only believer in a PTX turnaround, and by the way the share price has been acting during the past month, many investors are also alive and well in the PTX long camp. When stocks tick higher, retail investors are typically the last to know why, it’s for that reason that investors should keep a close eye on volatility and understand that erratic stock behavior isn’t necessarily a bad sign, rather it’s often a sign of significant news to come.

Admitting the problem is the first step in any recovery process. PTX management has admitted to having a problem long ago. Since then, they have been working on a solution and from an investor’s point of view, appear to be making significant progress. For me, I can’t abandon a work in progress, and as long as I believe that PTX is working diligently on a favorable solution and has a long-term vision for the company, hanging tight may be worth my while.

In the meantime, I’ll stay long and stay patient, and if the stock continues to get beaten around, all I can say at that point is, “please sir, may I have another.”

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I am long PTX and may purchase additional shares within the next 72 hours.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 479
Achillion Pharmaceuticals, Inc. ACHN Stock News

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Achillion Pharmaceuticals is having a strong start in the pre-market hours today, and for good reason. The commpany has been issued a patent. As a result, the stock is soaring, and as soon as the gains started, our partners at Trade Ideas alerted us of the movement. At the moment (8:34), ACHN is trading at $4.00 per share after a gain of $0.16 per share or 4.17% thus far today.





ACHN Awarded Patent

As mentioned above, Achillion Pharmaceuticals is having a strong time in the market after being awarded a patent. The patent surrounds compositions of matter for compounds that inhibit complement factor D activity. This is a key mediator in the complement alternative pathway, also known as AP. In a statement, Millind Deshpande, Ph.D., President and CEO at ACHN had the following to offer with regard to the patent…

Achillion’s aim is to establish a broad patent portfolio for its complement program. With the granted of this first patent we are pleased that the USPTO has confirmed that Achillion possesses a multitude of patentable complement factor D inhibitors… As a leader in AP biology, we are proud to have been the first to clinically demonstrate, in healthy volunteers, the ability to suppress AP activity following oral dosing of our complement factor D inhibitor, ACH-4471. The receipt of this patent, along with the number of additional patent applications under review by the USPTO, strengthens our position as a leader in factor D inhibitors for the potential treatment of AP-mediated diseases, such as C3G, PNH and geographic atrophy.”




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching ACHN incredibly closely. In particular, we’re interested in following the company’s ongoing work with regard to ACH-4471. Nonetheless, we’ll continue to follow the story closely and bring you the updates as they break.

What Do You Think?

Where do you think ACHN is headed moving forward?

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 744
Moleculin Biotech Inc MBRX Stock News

Moleculin Biotech Inc (NASDAQ: MBRX)

Moleculin Biotech is having a great start to the day in the pre-market hours after receiving Orphan Drug Designation from the FDA. Our partners at Trade Ideas were the first to alert us of gains on the stock a short while ago, and we’re glad they did. At the moment (7:35), MBRX is trading at $1.07 per share after a gain of $0.15 per share (14.02%) thus far today. So, what’s the deal? Why is the stock gaining? Here’s the scoop…





What’s Going On With MBRX?

Truth be told, this one took a little time to dig up. Unfortunately, none of the news agencies seem to be covering the news on Moleculin Biotech, and surprisingly, given the good news we’ll share in a second here, the company has not yet launched a press release. Nonetheless, we were able to find the reason for the gains on the United States Food and Drug Administration website.

The news is that MBRX has been granted Orphan Drug Designation for its lead candidate. The candidate, liposomal annamycin, is designed for the treatment of myeloid leukemia and has been granted the designation given the overwhelming need for a treatment in this debilitating and life-threatening condition.




What Does Orphan Drug Designation Mean For Moleculin Biotech?

Orphan Drug Designation is a designation that is given to medications designed to treat rare diseases. The designation means that MBRX will have an easier time getting the treatment through the approval process. It also means that the company will have better tools for protecting its intellectual property associated with the treatment. All in all, Orphan Drug Designation is overwhelmingly positive news that will be a benefit to both the company and its shareholders.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be following MBRX incredibly closely. In particular, we’re interested in watching the process of ongoing work associated with liposomal annamycin. Considering the Orphan Drug Designation, things seem to be going swimmingly at the moment and will likely stay on this track. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 285
Pingtan Marine Enterprise Ltd PME Stock News

Pingtan Marine Enterprise Ltd (NASDAQ: PME)

 Pingtan Marine (PME) is holding on to its early gains, trading over 7% higher in early trading. Currently , the stock is trading at $4.18 (12:01est), down from its intraday high of $4.46 a share. Our partners at Trade Ideas provided the alert.





What’s Fishing At PME?

On Tuesday, PME announced that the company has begun development of a new processing factory in Pingtan Comprehensive Experimental Area, Fulian, PRC. The new facility will be developed to serve as PME’s primary storage, processing, and distribution base.

PME, a global fishing company based in the People’s Republic of China, indicated that the processing factory will be located on a site of 40,000 square meters, and that the annual storage capacity is expected to be 500,000 tons. Additional facilities to be constructed will include one 50,000 tonnage cold storage, a complete set of intensive processing workshop and associated primary processing and packaging workshops as well as one warehouse, covering an overall floorage of 81,654 square meters. The finished facilities will be ultimately used for cold storage, processing and distribution of the deep ocean fish landings of Pingtan’s vessels. The processing factory is expected to begin service upon completion of construction in 2018.In light of a greater emphasis on food safety in recent years, the Company believes that there is a significant demand among the Chinese population for natural ocean products harvested and processed directly by pelagic fishing company.




PME’sChairman and CEO, Mr. Xinrong Zhou, commented, “We are very pleased to announce that after two years of preparation, GDOF is moving forward with the construction of the fish processing factory, which marks our first step into the consumer food processing market. We intend to address the growing demand for deep-ocean fish products in the China domestic market while also enhancing the deployment of new fishing fields and new vessels. Pingtan has begun to focus on participating in the supply chain by integrating both the harvesting and processing of ocean products and the expansion of not only our presence and market share in mainland China but also the business reputation of Pingtan as a brand. Through GDOF, we aim to complete construction and begin operations of the processing factory as scheduled. We believe the facilities will contribute to the further development of Pingtan’s business operations.”

With China being a significant market, and as a country that often takes care of its own companies first, PME may be an attractive stock to keep an eye on. However, as with many emerging PRC companies, be sure to read the SEC filings and stay current with breaking news and political rhetoric.

As always, CNA Finance will keep followers apprised of any additional breaking news for PME.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 402
EXACT Sciences Corporation EXAS Stock News

EXACT Sciences Corporation (NASDAQ: EXAS)

EXACT Sciences was off to what seemed like it was going to be an overwhelmingly rough day in the market today. After starting the day in the green, the stock started to bounce around a bit before diving down toward the bottom. However, minutes ago, the stock started to spike back upward and now, it seems to be nearing the green. Below, we’ll talk about what we’re seeing from EXAS, why, and what we’ll be watching for ahead.





What We’re Seeing From EXAS

As mentioned above, EXACT Sciences isn’t having the best of days in the market today. Sure, the stock started the day in the green, but after bouncing around a bit, it quickly spiked deep into the red. However, minutes ago, the direction changed as the stock pushed back toward the break even point. Currently (11:59), EXAS is trading at $20.93 per share after a loss of $0.30 per share or 1.39% thus far today.

What’s Happening With The Stock

Before we get too deep into the details, it’s important that we give credit where credit is deserved. Our partners at Trade Ideas were the first to inform us of the gains on EXAS. As soon as we received the notification, the CNA Finance team started digging to see what caused the reversal. It didn’t take long to dig up the story.




You see, early morning declines happened as news broke that Exact Sciences canceled its appearance at the Deutsche Bank Conference. However, the reversal happened as the company released why. According to Benzinga, the company cited scheduling conflicts as the reason for missing the confrence. The company intends on reporting earnings prior to the dates of the conference. EXAS has also reaffirmed plans to attend the Bank of America Health Care conference.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on EXAS. In particular, we’re interested in following the company through earnings as well as the Bank of America conference. Nonetheless, we’ll continue to watch the stock closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 860
Pulmatrix Inc PULM Stock News

Pulmatrix Inc (NASDAQ: PULM)

Pulmatrix is spiking in the morning session, currently up over 35% to $3.76 a share (11:11EST). PULM traded as high as $3.90 earlier in the session. Our partners at Trade Ideas provided the trading alert.





What’s The Deal?

For PULM, the news is a milestone. The company announced that the EU has granted the company a key patent covering PULM’s proprietary method of delivering drugs directly to the lungs, eliminating compromised dosing of drugs that often get caught in the throat or mouth. PULM’s technology uses dry powders that “fly” easily into the lungs, delivering maximum dose and increasing potential efficacy of the treatment. The technology is expected to prove useful for a variety of drugs, maximizing therapeutic benefit with efficient delivery to the lungs.




Robert W. Clarke, Ph. D., CEO of PULM, stated, “This new patent shows our continued ability to obtain patents that protect our unique iSPERSE inhaled drug technology—and that also reflect the advances we are making in drug delivery,” He continued by saying, “It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates for COPD, fungal infections, and other diseases.”

The new EU patent granted to PULM, (EP 2410981 B1) , fortifies and follows on similar patents that Pulmatrix has been granted in the United States and Japan. PULM’s most important patent is US 9,433,576, which provides broad protection to PULM’s innovative drug delivery technologyand to its use to treat a wide variety of diseases.

What Now For PULM?

The patent news is validating, and for a company like PULM, this type of broad drug delivery technology may lead to lucrative partnership potential. With the lungs requiring acute attention when being treated, adding the ability to maximize dosage and to directly target the therapy in the lungs is a milestone achievement.

With the stock trading 35% higher on strong volume, investors like what they see and clearly recognize the potential that the patent may bring to PULM.

CNA Finance will keep followers posted of any breaking news on PULM.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 443
Biogen Inc BIIB Stock News

Biogen Inc (NASDAQ: BIIB)

Biogen is having an interesting day in the market today, to say the least. At the opening bell, the stock was trading in the green. From there, it dipped down a bit, but caught itself before going red. Nonetheless, things changed in a big way minutes ago as the stock started to skyrocket following news of a patent decision. Below, we’ll talk about what we’re seeing from BIIB, why, and what we’ll be watching for ahead.





What We’re Seeing From BIIB

As mentioned above, Biogen is having a good day in the market today. After starting the day off in the green, the stock fell a bit. However, just before the stock hit the red, it started to recover. Then, the good day turned great minutes ago as the stock started to climb dramatically. At the moment (10:26), BIIB is trading at $280.81 per share after a gain of $6.01 per share (2.19%) thus far today.

Why The Stock Is Headed Upward

As is nearly always the case, our partners at Trade Ideas were the first to inform us of the gains on BIIB. As soon as we received the alert, the CNA Finance team started digging to see why the stock was making a run for the top. It didn’t take long to dig up the story. Ultimately, the gains are the result of excitement surrounding a patent decision.




Minutes ago, news came down the wire with regard to the ‘514 Tecfidera patent. The patent has been at the center of a patent battle, in which Biogen has been working to protect its intellectual property. That’s why the news that was released was overwhelmingly positive. The US Patent Trial and Appeal Board has made the decision to uphold the patent, maintaining the company’s IP rights. As a result, investor excitement ensued, leading to gains in the stock.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on BIIB. In particular, we’ll be watching as the company continues to innovate, considering its overwhelmingly strong pipeline. We’ll continue to follow the story closely and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

This Morning On CNA Finance PTIE GEL ATNM AST HTBX GNC Stock News

This morning has been a pretty active one in the market with movement in both directions. Here’s a brief overview of great opportunities that the CNA Finance team has found in the market so far this morning…





Stocks Headed Up – GNC, HTBX, AST, ATNM, PTIE

  • GNC Holdings (GNC) Stock: This morning, a rumor broke that GNC would be taken over by a Chinese suitor. There are no details with regard to who that suitor may be or at what price the takeover might happen. Read the full story here.
  • Heat Biologics (HTBX) Stock: This morning, Heat Biologics released positive clinical data that sent the stock soaring. Read the full story here.
  • Asterias Biotherapeutics (AST) Stock: Asterias Biotherapeutics also released incredibly positive clinical data from an ongoing clinical trial. As a result, the stock has been headed up. Read the full story here.
  • Actinium Pharmaceuticals (ATNM) Stock: Actinium Pharmaceuticals has been headed upward this morning after a releasing a PR announcing that it has a clear pathway toward EU regulatory approval. Read the full story here.
  • Pain Therapeutics (PTIE) Stock: Finally, Pain Therapeutics announced positive regulatory guidance this morning, causing a frenzy among investors and sending the stock upward. Read the full story here.




Stocks Headed Down – GEL

  • Genesis Energy (GEL) Stock: So far this morning, we have only covered one falling stock. That stock is Genesis Energy. Unfortunately the stock is falling as the result of a secondary offering. Read the full story here.

Stay Tuned!

CNA Finance is following all of these stories incredibly closely and will be providing updates as they break. Don’t miss the news! Stay tuned!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 3774
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...